文献速递免疫规划慢病防控与筛查

mRNA与阿斯利康COVID-19疫苗在自身免疫性风湿病患者中的有效性与安全性:一项系统综述

Efficacy and safety of mRNA and AstraZeneca COVID-19 vaccines in patients with autoimmune rheumatic diseases: A systematic review.
PubMed 文献 · Vaccine · 2023-05-22

该系统综述检索PubMed、EMBASE和OVID数据库至2022年4月13日,纳入60项预后研究、69篇病例报告与病例系列及8部国际临床实践指南,评估mRNA与阿斯利康COVID-19疫苗在自身免疫性风湿病患者中的有效性与安全性;结果显示多数患者接种两剂后能产生体液和/或细胞应答,但接受利妥昔单抗、甲氨蝶呤、吗替麦考酚酯、每日糖皮质激素>10 mg、阿巴西普者及老年人、合并间质性肺病患者应答欠佳;安全性报告总体令人安心,不良事件多为自限性,接种后疾病 flare 极少。

要点

  • 多数自身免疫性风湿病患者接种两剂COVID-19疫苗后可产生体液和/或细胞应答。
  • 接受利妥昔单抗、甲氨蝶呤、吗替麦考酚酯、每日糖皮质激素>10 mg、阿巴西普者及老年人、合并间质性肺病患者应答欠佳。
  • 安全性报告总体令人安心,不良事件多为自限性,接种后疾病 flare 极少。

核心结论

  • mRNA与阿斯利康COVID-19疫苗在自身免疫性风湿病患者中高度有效且安全。
  • 由于部分患者应答欠佳,应同时采取加强针和防护措施等替代缓解策略。
  • 围疫苗接种期免疫调节治疗方案的管理应通过与患者及其风湿科主治医师共同决策个体化制定。

研究设计与样本

  • 系统综述,检索PubMed、EMBASE和OVID数据库至2022年4月13日。
  • 纳入60项预后研究、69篇病例报告与病例系列、8部国际临床实践指南。
  • 使用预后研究质量工具评估纳入研究的偏倚风险。

主要发现

  • 多数自身免疫性风湿病患者接种两剂COVID-19疫苗后能产生体液和/或细胞应答。
  • 接受利妥昔单抗、甲氨蝶呤、吗替麦考酚酯、每日糖皮质激素>10 mg、阿巴西普的患者应答欠佳。
  • 老年人和合并间质性肺病的患者应答亦欠佳。
  • 安全性报告总体令人安心,不良事件多为自限性,接种后疾病 flare 极少。

临床怎么用

  • 作者建议对部分应答欠佳的患者采取加强针和防护措施等替代缓解策略。
  • 作者建议围疫苗接种期免疫调节治疗方案的管理通过与患者及其风湿科主治医师共同决策个体化制定。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with autoimmune rheumatic diseases (ARD) are at a potentially higher risk for COVID-19 infection complications. Given their inherent altered immune system and the use of immunomodulatory medications, vaccine immunogenicity could be unpredictable with a suboptimal or even an exaggerated immunological response. The aim of this study is to provide real-time data on the emerging evidence of COVID-19 vaccines' efficacy and safety in patients with ARDs. METHODS: We performed a literature search of the PubMed, EMBASE, and OVID databases up to 11-13 April 2022 on the efficacy and safety of both types of the mRNA-vaccines and the AstraZeneca COVID-19 vaccines in patients with ARD. The risk of bias in the retrieved studies was evaluated using the Quality in Prognostic Studies tool. Also, current clinical practice guidelines from multiple international professional societies were reviewed. RESULTS: We identified 60 prognostic studies, 69 case reports and case series, and eight international clinical practice guidelines. Our results demonstrated that most patients with ARDs were able to mount humoral and/or cellular responses after two doses of COVID-19 vaccine although this response was suboptimal in patients receiving certain disease-modifying medications including rituximab, methotrexate, mycophenolate mofetil, daily glucocorticoids >10 mg, abatacept, as well as in older individuals, and those with comorbid interstitial lung diseases. Safety reports on COVID-19 vaccines in patients with ARDs were largely reassuring with mostly self-limiting adverse events and very minimal post-vaccination disease flares. CONCLUSION: Both types of the mRNA-vaccines and the AstraZeneca COVID-19 vaccines are highly effective and safe in patients with ARD. However, due to their suboptimal response in some patients, alternative mitigation strategies such as booster vaccines and shielding practices should also be followed. Management of immunomodulatory treatment regimens during the peri vaccination period should be individualized through shared decision making with patients and their attending rheumatologists.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Joudeh AI, Lutf AQ, Mahdi S, et al. Efficacy and safety of mRNA and AstraZeneca COVID-19 vaccines in patients with autoimmune rheumatic diseases: A systematic review. Vaccine. 2023. PMID: 37244811. doi:10.1016/j.vaccine.2023.05.048

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。